Impact Therapeutics Inc.

Eikon Therapeutics has raised another venture capital mega-round – bringing its total funding to date to $1.1bn – to build what it calls a “21st century biotechnology company.” The new financing will

Amid a persistent funding crunch in November, Chinese biotechs managed to edge close to bigger fund-raising deals backed by venture capital and private equity firms. Apart from a $100m-plus series A+

Perhaps reflecting recent global big pharma interest in the sector, Chinese biotechs focused on radiopharmaceuticals have been extending their fundraising spree since March, with three major financing

AstraZeneca may just have found a worthy successor to its blockbuster PARP inhibitor drug Lynparza. New Phase I/II results from the next generation therapy saruparib just unveiled suggest that it cou